Title:Antibody Responses and CNS Pathophysiology of Mucormycosis in
Chronic SARS Cov-2 Infection: Current Therapies Against Mucormycosis
Volume: 29
Issue: 32
关键词:
粘膜真菌病、皮质类固醇、抗真菌治疗失败、临床报告、中枢神经系统病理生理学、慢性SARS Cov-2、抗体反应。
摘要: The incidence rate of opportunistic secondary infections through invasive fungi
has been observed to be 14.5% to 27% in the SARS CoV pandemic during the year
2003. However, the incidence of SARS CoV-2 is accompanied by a substantial rise in secondary
opportunistic infections like mucormycosis (black fungus), mainly in the immunocompromised
individuals and diabetic patients taking steroids. Substantial rates of
COVID-19 cases with mucormycosis were reported in India and other parts of the world.
Previous research reports delineated the ability of Mucorales to invade the various tissues
like lungs, brain, and sinus through the GRP78, and subsequently, this infection could invoke
crusting, edema, and necrosis of the brain parenchyma, ptosis, proptosis, and vision
loss due to intraorbital and intracranial complications. Similarities of these pathophysiological
complications with already existing diseases are causing clinicians to face several
challenges in order to diagnose and treat this disease effectively at the early stage. This
minireview depicts the mucormycosis-induced immune and pathophysiological alterations
in COVID-19 patients comorbid with diabetes and immunosuppression and also reported
the various clinical manifestations, the therapeutic modalities, and the failures of
anti-fungal vaccines. Therefore, the emerging mucormycosis in COVID-19 patients
needs rapid investigation and selective optimization of the effective therapeutic modalities,
including antifungal vaccines, to minimize the mortality rate.
